16 results about "Gabapentin enacarbil" patented technology

This invention provides a drug related to lung injury and its application, the drug comprising gabapentin and / or pharmaceutically acceptable salts of gabapentin; the drug reduces the levels of MPO and NOX2 in lung tissue; the application is for the preparation of formulations for the prevention or treatment of lung injury using gabapentin and / or pharmaceutically acceptable salts of gabapentin, or for the study of the mechanism of lung injury caused by surgery; the study is related to manufacturing and application in industry; the drug can prevent or treat damage caused by lung interruption and re-inflation during lung surgery, and has good application prospects in industry.

The present invention relates to a synergistic admixture of Gabapentin and Ketoprofen, preferably Ketoprofen Lysine, to a pharmaceutical composition comprising said admixtures and to the use of said admixtures or pharmaceutical compositions in the treatment of acute or chronic pain, in particular in the treatment of neuropathic or inflammatory pain.

The application relates to the technical field of recrystallization, in particular to a preparation method of high-purity gabapentin, which comprises the following steps: S1, detecting first impurities and second impurities; S2, judging the opening and closing of a baffle according to the impurities; S3, conveying a preset weight of gabapentin to a preset working group; S4, opening the preset working group; S5, precipitating the first impurities and conveying a preset weight of gabapentin to the preset working group; S6, opening the preset working group; S7, precipitating the second impurities and recovering the impurities and the gabapentin; and S8, judging whether the recrystallization is completed or not. The special recrystallization device is added in the preparation method, the problems that the existing gabapentin recrystallization device has low production efficiency and cannot realize large-scale automatic production can be solved, the automatic degree in the recrystallization process is greatly increased, the problem that a large number of high-level technical personnel are needed to operate in the gabapentin recrystallization process is solved, the labor cost in the gabapentin recrystallization process is greatly reduced, and the economic benefits are increased.

The present disclosure provides methods of determining whether or not to administer a subject gabapentin, said method comprising assessing the genetic profile of a subject considered for a gabapentin-based therapy and determining, on the basis of the genetic profile, whether or not to administer the subject gabapentin.

The invention belongs to the technical field of medicines, and particularly relates to a soluble gabapentin microneedle patch as well as a preparation method and application thereof. The gabapentin micro-needle provided by the invention is prepared from gabapentin, hyaluronic acid, anesthetic and water according to a specific ratio through a negative pressure centrifugation method, the micro-needle can penetrate through a skin cuticle, the medicine can be quickly dissolved and released within 10 minutes, and the problems of slow effect and low bioavailability of traditional administration are effectively solved; the pharmaceutical composition has excellent mechanical strength and safety, is free of skin irritation and organ toxicity, is specially used for relieving or treating stress, anxiety, fear and epilepsy symptoms, has the effects of calming, assisting in analgesia and soothing emotion, and remarkably improves the administration convenience and compliance.

The present invention relates to use of botulinum toxin type E for preventing or treating neuropathic pain, and specifically, to a pharmaceutical composition comprising botulinum toxin type E for preventing or treating neuropathic pain, and a surgical operation analgesic comprising botulinum toxin type E as an active ingredient. The botulinum toxin type E of the present invention has an analgesic effect by significantly inhibiting neuropathic pain, and, after a single administration, the botulinum toxin type E of the present invention can alleviate side effects and provide an analgesic effect superior to that of Gabapentin, which is a conventional analgesic used for treating neuropathic pain, in mechanical allodynia caused by mandibular alveolar nerve injury. In addition, the botulinum toxin type E of the present invention has a short duration of analgesic action in the body after administration so as to enable faster recovery and rehabilitation than after administration of botulinum toxin type A, and thus can be effectively used for treatment of neuropathic pain.

The invention belongs to the field of biological medicine, and discloses an AER270 diagnosis and treatment prodrug with hypochlorous acid response characteristic as well as a preparation method and application thereof, the AER270 diagnosis and treatment prodrug has a structure as shown in a general formula I. Based on a core structure of methylene blue (MB), gamma-aminobutyric acid (GABA), gabapentin or aminopropanol is used as a connecting chain, and is coupled with an AQP4 inhibitor AER270 through an ester bond or an ether bond, so that the prodrug is prepared. According to the present invention, the HOCl specific activation rupture release active molecules AER270 and GABA or gabapentin is achieved, the penetrability on the blood brain barrier and the selective treatment on the cerebral apoplexy focus are enhanced, the reduced methylene blue molecule is released, the cerebral apoplexy focus can be specifically lightened, and the diagnosis and treatment integration is achieved.

The present invention provides methods of treating cannabis withdrawal syndrome and other cannabis related conditions, including cannabis use disorder, in a subject, comprising administering to the subject in need thereof an effective amount of a cannabinoid or an effective amount of a cannabinoid and an effective amount of a second active agent, such as gabapentin or a gabapentin analog.

This invention belongs to the field of pharmaceutical technology, specifically relating to soluble gabapentin microneedle patches, their preparation methods, and applications. The microneedles provided by this invention are prepared by negative pressure centrifugation using gabapentin, hyaluronic acid, anesthetic, and water in a specific ratio. These microneedles can penetrate the stratum corneum of the skin, rapidly dissolving and releasing the drug within 10 minutes, effectively solving the problems of slow onset and low bioavailability in traditional drug administration. They also possess excellent mechanical strength and safety, with no skin irritation or organ toxicity, and are specifically designed to relieve or treat symptoms of stress, anxiety, fear, and epilepsy, providing sedation, adjunctive analgesia, and emotional calming effects, significantly improving the convenience and compliance of drug administration.

The application discloses a biological adhesive tape for a nerve stump after amputation and a preparation method thereof. The biological adhesive tape comprises an outer layer and an inner layer, and the outer layer and the inner layer are connected by a PEG-based adhesive layer. The outer surface of the outer layer is coated with a PDMS hydrophobic coating layer. The inner surface of the inner layer is also coated with a PEG-based adhesive layer. The outer layer is made of recombinant human collagen type I and contains dexamethasone drug-loaded microspheres. The inner layer is made of recombinant human collagen type I and contains gabapentin drug-loaded microspheres. The outer layer of the biological adhesive tape can inhibit inflammatory response and reduce foreign body reaction by releasing glucocorticoids. The inner layer can prevent and relieve neuropathic pain by releasing gabapentin. The physical adhesion of the adhesive tape can prevent the growth of nerve fibers outward, thereby reducing the risk of neuroma formation. The biological adhesive tape has high flexibility in application, is suitable for nerve stumps with different diameters and shapes, and is suitable for complex trauma.

The invention provides a gabapentin sustained release tablet as well as a preparation method and application thereof, and belongs to the technical field of medical preparations, the gabapentin sustained release tablet is prepared by uniformly mixing gabapentin, HPMC-K15M, PEO 303, CP, NaHCO3, a filling agent, an adhesive and a flow aid, and tabletting; the gabapentin sustained release tablet is used for relieving animal stress response. According to the gabapentin sustained-release preparation, by optimizing the proportion of the auxiliary materials, first-stage sustained-release kinetics of gabapentin is achieved, the stability of the preparation is improved through the combination of the auxiliary materials, and burst release or incomplete release is avoided.

The present invention relates to a new co-crystal of Gabapentin, Ketoprofen and Lysine, to pharmaceutical compositions and to their use in the prevention, reduction or treatment of pain and / or inflammation.

The present disclosure relates to an industrially feasible and economically viable process for preparation of Gabapentin of formula (I) which is shown below: (I)

The invention relates to the technical field of biological medicines, and provides application of a BCAA inhibitor in preparation of medicines for inhibiting, preventing, relieving or treating mutant leukemia aiming at the problems of high drug resistance, high recurrence rate and limited treatment effect in treatment of DNMT3A mutant AML patients at present. The BCAA inhibitor is gabapentin and / or cytarabine arabinoside. Experiments prove that gabapentin has a treatment effect on DNMT3A mutated acute myelogenous leukemia, meanwhile, it is found that DNMT3A mutated acute myelogenous leukemia cells have drug resistance to cytarabine, and the gabapentin and the cytarabine are combined to have a synergistic effect on the DNMT3A mutated acute myelogenous leukemia. The discovery of the application provides a new thought and direction for treatment of mutant leukemia, especially acute myelogenous leukemia with DNMT3A mutation.

The application discloses a small-molecule twin drug compound with synergistic analgesic effect, a pharmaceutical composition, a preparation method and application thereof. The twin drug molecule is formed by covalently connecting a drug A and a drug B, wherein the drug A is nefopam, and the drug B is gamma-aminobutyric acid (GABA) and an analogue thereof, including gabapentin, pregabalin, GABA, methoxycarbonyl-gamma-aminobutyric acid (MGB), and cligabalin. The analgesic efficacy of the twin drug molecule is superior to that of combined administration and single drug, the twin drug molecule can obviously improve various acute and chronic inflammatory pains and relieve peripheral neuropathic pain induced by paclitaxel, has higher anti-inflammatory activity than that of combined administration and single drug, and thus has the potential to treat pain, inflammation and inflammation-related diseases, and can effectively reduce the interaction between drugs and increase the medication compliance of patients.